San Diego’s has added another successful business to its budding biotech hub. Start-up firm aTyr Pharma, Inc. drew over $76 million investment capital from Sofinnova Ventures and another undisclosed entity to develop its drug called Resolaris that helps treat muscular dystrophy (Fikes, 2015). Biotech firms like aTyr help encourage greater investment and employment in the San Diego economy. Every investment opportunity comes with risk and rewards. Venture capitalists diligently assess whether the risks and rewards are worth investing their hard earned capital. Risk tolerant investors are more likely to get involved in highly innovative startups (Tian & Wang, 2014). In this case, a single patentable and profitable drug can make or break the firm’s long-term future. The ability to have exclusive rights to manufacture an important drug can be worth hundreds of millions of dollars. Approval of Resolaris for use and testing in the E.U., U.S. and other markets will add si
The blog discusses current affairs and development of national economic and social health through unique idea generation. Consider the blog a type of thought experiment where ideas are generated to be pondered but should never be considered definitive as a final conclusion. It is just a pathway to understanding and one may equally reject as accept ideas as theoretical dribble. New perspectives, new opportunities, for a new generation. “The price of freedom is eternal vigilance.”—Thomas Jefferson